United States

Securities and Exchange Commission

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ending September 30, 2013

¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____to_____

Commission file number: 0-30520

GLOBAL IMMUNE TECHNOLOGIES, INC.

(Name of registrant as specified in its Charter)

Wyoming		98-05327255
(State of Incorporation)		(IRS Employer Identification No.)

110 Main Street, Suite 201, Burlington, VT		05401
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:

802-540-0745

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer.

Large accelerated filer ¨ Accelerated file ¨ Non-accelerated filer ¨ Smaller reporting company x.

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ¨ No x

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act subsequent to the distribution of securities under a plan confirmed by the court. Yes ¨ No ¨ N/A

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of September 30, 2013 we had 157,349,731shares of common stock issued and outstanding and as of July 31, 2013 we had 65,349,731 shares of common stock issued and outstanding.

Table of Contents

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION	3

Item 1. Financial Statements	3

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3. Quantitative and Qualitative Disclosures about Market Risk	16

Item 4. Controls and Procedures	16

PART II. OTHER INFORMATION	18

Item 1. Legal Proceedings	18

Item 1A. Risk Factors	18

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds	18

Item 3. Defaults upon Senior Securities	19

Item 4. Mine Safety Disclosures	19

Item 5. Other Information	19

Item 6. Exhibits	19

Signatures	20

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Global Immune Technologies, Inc.

(A Development Stage Company)

Balance Sheets

As of September 30, 2013 and March 31, 2013

ASSETS	30-Sep-13			31-Mar-13

Current assets:
Cash	$	12,794		$	92,038
Accounts receivable		1,500			1,100
Total Current Assets	$	14,294		$	93,138

Other assets:
Receivable from employees		82,562			46,455


Total Assets	$	96,856		$	139,593


LIABILITIES & SHAREHOLDERS' DEFICIT

Current liabilities:
Accounts payable & accrued expenses	$	224,247		$	245,437
Subscriptions payable		0			172,937
Convertible note payable		65,000			32,500
Due to employees		38,779			0
Due to related parties		417,512			417,512
Total Current Liabilities	$	745,538		$	868,386

Shareholder's Deficit:
Authorized 500,000,000 shares, issued and outstanding, no par value 140,197,613 outstanding at March 31, 2013 and 157,349,731 at September 30, 2013	$	4,561,228		$	4,092,187
Accumulated deficit- development stage		(5,214,452	)		(4,825,522	)
Accumulated comprehensive gain		4,542			4,542
Total Shareholders' Deficit		(648,682	)		(728,793	)

Total Liabilities & Shareholders' Deficit	$	96,856		$	139,593

Please see the notes to the financial statements.

Table of Contents

Global Immune Technologies, Inc.

(A Development Stage Company)

Statements of Operations

For the Six Months and Quarters Ended September 30, 2013 and

September 30, 2012 and From April 1, 1999 to September 30, 2013

(As Restated)

	6 Months			6 Months			3 Months			3 Months			From April 1, 1999
	30-Sep-13			30-Sep-12			30-Sep-13			30-Sep-12			to September 30, 2013

General & administrative expenses:
Management fees	$	148,531		$	46,000		$	52,467		$	35,667		$	492,914
Professional fees		27,125			6,500			21,075			6,500			592,018
Travel & entertainment		30,205			3,177			6,778			3,177			65,477
Transfer agent & filing fees		2,142			5,254			2			5,254			19,598
Automobile expense		0			6,257			(1,860	)		6,257			7,764
Foreign currency gain (loss)		16,218			0			16,218			0			25,009
Rent expense		0			0			0			0			74,177
General administration		250			1,272			71			1,272			338,285
Office supplies and sundry expenses		29,247			0			(688	)		0			164,839
Consulting expense		120,228			9,250			48,558			9,250			433,449

Net loss before other income (expense)	$	(373,946	)	$	(77,710	)	$	(142,621	)	$	(67,377	)	$	(2,213,530	)

Interest expense		(14,984	)		0			0			0			(29,463	)
Deferred expenses written off		0			0			0			0			(318,404	)
Forgiveness of debt		0			0			0			0			145,450
Gain on sale of mineral rights		0			0			0			0			110,859
Legal settlement		0			0			0			0			129,031
Other write offs		0			0			0			0			(607,353	)
Translation adjustment		0			0			0			0			(187,015	)

Net loss from continuing operations	$	(388,930	)	$	(77,710	)	$	(142,621	)	$	(67,377	)	$	(2,970,425	)

Net loss from discontinued operations		0			0			0			0			(193,075	)

Net loss	$	(388,930	)	$	(77,710	)	$	(142,621	)	$	(67,377	)	$	(3,163,500	)

Basic & diluted loss per share	$	(0.00	)	$	(0.00	)	$	0.00		$	0.00

Weighted average of common shares outstanding		147,929,934			140,197,613			140,197,613			140,197,613

Please see the notes to the financial statements.

Table of Contents

Global Immune Technologies, Inc.

(A Development Stage Company)

Statements of Cash Flows

For the Six Months Ended September 30, 2013 and September 30, 2012 and

From April 1, 1999 to September 30, 2013

							From April 1, 1999
	30-Sep-13			30-Sep-12			to September 30, 2013
Operating activities:
Net loss	$	(388,930	)	$	(77,710	)	$	(3,163,500	)
Adjustments to reconcile net loss items not requiring the use of cash:
Consulting fees & services expense		0			0			207,379
Translation adjustment		0			0			187,015
Interest expense		14,984			0			29,463
Accounts receivable		(400	)		0			(1,500	)
Receivable from employees		(36,107	)		0			(82,562	)
Subscriptions payable		(172,937	)		5,800			0
Accounts payable		(21,190	)		0			224,247
Due to employees		38,779			0			38,779
Due to related parties		0			79,500			417,512
Net cash used by operations	$	(565,801	)	$	7,590		$	(2,143,167	)

Financing activities:
Private placement	$	454,057		$	0		$	1,105,006
Stock options exercised		0			0			523,508
Proceeds convertible notes issued		32,500			0			65,000
Debentures issued		0			0			165,477
Net cash provided by financing activities		486,557			0			1,858,991

Net increase (decrease) in cash during the period	$	(79,244	)	$	7,590		$	(284,176	)

Cash balance at beginning of fiscal year		92,038			0			296,970

Cash balance at end of period	$	12,794		$	7,590		$	12,794


Supplemental disclosures of cash flow information:
Interest paid during the period	$	0		$	0
Income taxes paid during the period	$	0		$	0

Please see the notes to the financial statements.

Table of Contents

Global Immune Technologies, Inc.

(A Development Stage Company)

Statements of Shareholders’ Equity

From April 1, 1999 to September 30, 2013

							Development				Accumulated
	Common						Stage				Comprehensive
	Shares			Equity			Deficit				Income				Total

Balance at March 31, 1999		3,029,415			$	2,137,247		$	(2,050,952	)		$	0			$	86,295

Exchanged shares for debt		838,679				108,302											108,302
Private placement		1,000,000				210,532											210,532
Stock options exercised		2,563,474				399,260											399,260
Net loss for the fiscal year									(563,508	)							(563,508	)

Balance at March 31, 2000		7,431,568			$	2,855,341		$	(2,614,460	)		$	0			$	240,881

Net loss for the fiscal year									(253,077	)							(253,077	)

Balance at March 31, 2001		7,431,568			$	2,855,341		$	(2,867,537	)		$	0			$	(12,196	)

Reverse stock split (5 for 1)		(5,945,252	)														0
Stock options exercised		497,329				51,248											51,248
Private placement		150,000				19,242											19,242
Issued shares for acquisition		2,675,000				1											1
Issued shares for assignment of agreement		2,000,000				175,098											175,098
Exchanged shares for debt		400,000				10,262											10,262
Debentures converted to shares		6,450,000				165,477											165,477
Net loss for the fiscal year									(613,406	)							(613,406	)

Balance at March 31, 2002		13,658,645			$	3,276,669		$	(3,480,943	)		$	0			$	(204,274	)

Issued stock for services		137,000				8,485											8,485
Net loss for the fiscal year									(79,105	)							(79,105	)

Balance at March 31, 2003		13,795,645			$	3,285,154		$	(3,560,048	)		$	0			$	(274,894	)

Issued stock for services		2,400,000				55,430											55,430
Net loss for the fiscal year									(106,831	)							(106,831	)

Balance at March 31, 2004		16,195,645			$	3,340,584		$	(3,666,879	)		$	0			$	(326,295	)

Net loss for the fiscal year									(140,582	)							(140,582	)
Currency translation adjustment						99,486							(1,790	)			97,696
Balance at March 31, 2005		16,195,645			$	3,440,070		$	(3,807,461	)		$	(1,790	)		$	(369,181	)

Table of Contents

						Development				Accumulated
	Common					Stage				Comprehensive
	Shares		Equity			Deficit				Income				Total

Contribution of services					25,456											25,456
Net loss for the fiscal year								(94,957	)							(94,957	)
Currency translation adjustment												(4,018	)			(4,018	)

Balance at March 31, 2006		16,195,645		$	3,465,526		$	(3,902,418	)		$	(5,808	)		$	(442,700	)

Net loss for the fiscal year								(73,765	)							(73,765	)
Currency translation adjustment												9,532				9,532

Balance at March 31, 2007		16,195,645		$	3,465,526		$	(3,976,183	)		$	3,724			$	(506,933	)

Net loss for the fiscal year								(134,274	)							(134,274	)
Currency translation adjustment												818				818

Balance at March 31, 2008		16,195,645		$	3,465,526		$	(4,110,457	)		$	4,542			$	(640,389	)

Net loss for the fiscal year								(53,401	)							(53,401	)

Balance at March 31, 2009		16,195,645		$	3,465,526		$	(4,163,858	)		$	4,542			$	(693,790	)

Net loss for the fiscal year								(61,020	)							(61,020	)

Balance at March 31, 2010		16,195,645		$	3,465,526		$	(4,224,878	)		$	4,542			$	(754,810	)

Issued shares to consultants		99,694,508			76,945											76,945

Net loss for the fiscal year								(172,433	)							(172,433	)

Balance at March 31, 2011		115,890,153		$	3,542,471		$	(4,397,311	)		$	4,542			$	(850,298	)

Net loss for the fiscal year								(65,142	)							(65,142	)

Table of Contents

					Development			Accumulated
	Common				Stage			Comprehensive
	Shares		Equity		Deficit			Income		Total

Balance at March 31, 2012		115,890,153	$	3,542,471	$	(4,462,453	)	$	4,542	$	(915,440	)

Issuance of common stock		2,400,000		5,800							5,800
Stock options exercised		3,650,000		73,000							73,000
Issuance of convertible note				14,479							14,479
Issued shares to consultants		1,642,500		41,063							41,063
Issued shares for debt		16,614,960		415,374							415,374
Net loss for the fiscal year						(363,069	)				(363,069	)

Balance at March 31, 2013		140,197,613	$	4,092,187	$	(4,825,522	)	$	4,542	$	(728,793	)

Issuance of common stock		17,152,118		454,057							454,057
Issuance of convertible note				14,984							14,984
Net loss for the period						(388,930	)				(388,930	)

Balance at September 30, 2013		157,349,731	$	4,561,228	$	(5,214,452	)	$	4,542	$	(648,682	)

Please see the notes to the financial statements.

Table of Contents

Global Immune Technologies, Inc.

(A Development Stage Company)

Notes to the Financial Statements

For the Six Months Ended September 30, 2013 and September 30, 2012

1.	Organization of the Company and Significant Accounting Principles

Global Immune Technologies, Inc. (“the Company”) (formerly Secureview Systems, Inc.) was incorporated in 1985 as a British Columbia corporation. During the fiscal year ended in 2007, the Company re-domiciled to the State of Wyoming. Its business office is located in Burlington, Vermont.

The Company is considered a development stage company in accordance with the Statement of Financial Accounting Standards No. 7, “Accounting and Reporting for Development Stage Enterprises” (codified in ASC Topic 915, “Development Stage Entities”).

Use of Estimates- The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make reasonable estimates and assumptions that affect the reported amounts of the assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses at the date of the financial statements and for the period they include. Actual results may differ from these estimates.

Income taxes- The Company accounts for income taxes in accordance with generally accepted accounting principles which require an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for differences between financial statement and income tax bases of assets and liabilities that will result in taxable income or deductible expenses in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period adjusted for the change during the period in deferred tax assets and liabilities.

The Company follows the accounting requirements associated with uncertainty in income taxes using the provisions of Financial Accounting Standards Board (FASB) ASC 740, Income Taxes. Using that guidance, tax positions initially need to be recognized in the financial statements when it is more likely than not the positions will be sustained upon examination by the tax authorities. It also provides guidance for derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As of March 31, 2013 and September 30, 2013, the Company has no uncertain tax positions that qualify for either recognition or disclosure in the financial statements. All tax returns from fiscal years 2009 to 2012 are subject to IRS audit.

2.	Going Concern Discussion

The accompanying financial statements have been presented in accordance with generally accepted accounting principles, which assume the continuity of the Company as a going concern. The Company has no cash and relies upon the support of certain shareholders to pay its bills. The Company has incurred net losses since its inception and currently has no revenues to support its operations.

These factors raise doubt as to the Company’s ability to continue as a going concern.

Global Immune Technologies, Inc. is a Development Stage Company and consequently is subject to the risks associated with development stage companies, including the need for additional financing; the uncertainty of our business plan or business know-how or intellectual property resulting in successful commercial products or services as well as the marketing and customer acceptance of such products or services; competition from larger organizations; dependence on key personnel; and dependence on corporate partners and collaborators.

Table of Contents

The Company has been offering shares to persons interested in supplying us with capital to begin operations. We still have limited capital and will focus our initial operations to one or two such business locations to be able to take advantage of our proposed business opportunities. The Company intends to seek opportunities demonstrating the potential of long-term growth as opposed to short-term earnings. However, at the present time, the Company has not reached any agreement or definitive understanding with any person concerning an acquisition. Rather, we intend to build from start-up instead of incurring expensive acquisition costs.

The Company will need substantial capital to achieve its business plans. Management cannot provide assurance that its business plans will be achieved once its capital goals have been met nor can it provide an estimate on the level of capital that will be needed to achieve its business plan goals.

3. Fair Value of Financial Instruments

Fair Value Measurements under generally accepted accounting principles clarifies the principle that fair value should be based on the assumptions market participants would use when pricing an asset or liability and establishes a fair value hierarchy that prioritizes the information used to develop those assumptions. Under the standard, fair value measurements are separately disclosed by level within the fair value hierarchy as follows.

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.

Cash, accounts receivable, receivable from employee, accounts payables and accrued expenses, subscriptions payable, convertible note payable, due to employees, and payable to related parties in the balance sheet are estimated to approximate fair market value at September 30, 2013 and March 31, 2013 because of their short term nature.

4. Net Loss per Share

Basic net loss per share has been computed based on the weighted average of common shares outstanding during the period.

	30-Sep-13			30-Sep-12

Net loss	$	(388,930	)	$	(77,710	)

Weighted average shares outstanding		147,929,934			140,197,613

Basic & diluted loss per share	$	(0.00	)	$	(0.00	)

Table of Contents

5.	Related Party Transactions

The following table summarizes the related party payables owed by the Company to certain officers and shareholders.

	30-Sep-13		31-Mar-13

Don Perks- former president	$	225,755	$	225,755
Quebec Inc- warrant holder		135,500		135,500
Biaverde Investments- shareholder		39,021		39,021
Naaeem Tyab- creditor		17,236		17,236

Total related party payables	$	417,512	$	417,512

6.	Tax Provision

Provision for income taxes is comprised of the following:

	30-Sep-13			30-Sep-12
Net loss	$	(388,930	)	$	(77,710	)

Current tax expense:
Federal	$	0		$	0
State		0			0
Total	$	0		$	0

Less deferred tax benefit:
Timing differences		(800,488	)		(546,695	)
Allowance for recoverability		800,488			546,695
Provision for income taxes	$	0		$	0

A reconciliation of provision for income taxes at the statutory rate to provision for income taxes at the Company's effective tax rate is as follows:

	30-Sep-13			30-Sep-12
Statutory U.S. federal rate		34	%		34	%
Statutory state and local income tax		0	%		0	%
Less allowance for tax recoverability		-34	%		-34	%
Effective rate		0	%		0	%

Deferred income taxes are comprised of the following:

	30-Sep-13			30-Sep-12
Timing differences	$	800,488		$	546,695
Allowance for recoverability		(800,488	)		(546,695	)
Deferred tax benefit	$	0		$	0

Note: The deferred tax benefits arising from the timing differences expires in fiscal years 2020

through 2033 and may not be recoverable upon the purchase of the Company under current

IRS statutes.

Table of Contents

7.	Convertible Notes Payable

In March 2013, the Company issued a note to a financing company for $32,500. The note is unsecured and carries an interest rate of 8% and is due in December 2013. The note is convertible into common stock at an exercise price of 55% of the lowest market price of common stock of the sixty days preceding conversion.

In June 2013, the Company issued a note to a financing company for $32,500. The note is unsecured and carries an interest rate of 8% and is due in March 2014. The note is convertible into common stock at an exercise price of 55% of the lowest market price of common stock of the sixty days preceding conversion.

8.	Warrant Transactions

On December 4, 2012 the Company issued warrants to a related party, Quebec Inc, in consideration of an advance of $135,500. One warrant is for 10,425,000 shares of Common Stock at an exercise price of $0.02 expiring on December 4, 2013 and if exercised prior to expiration an “exploding” warrant for 5,212,500 at an exercise price of $0.25 expiring on December 4, 2014.

All warrants granted are recorded at fair value using a generally accepted warrant pricing model at the date of the grant. For purposes of determining the warrant value at issuance, the fair value of each warrant granted is measured at the date of the grant by the warrant pricing model with the following assumptions:

Dividend yield	0.00	%
Risk free interest rate	.25	%
Volatility	25.00	%

The fair values generated by warrant pricing model may not be indicative of the future values, if any, that may be received by the option holder. The fair value of the warrants issued generated by the warrant pricing model was zero at the date of the grant.

The following is a summary of common stock warrants outstanding at September 30, 2013

		Average	Average
		Exercise Price	Years to Maturity

Balance at March 31, 2013	10,425,000

Issues	0
Exercises	0
Expired	0

Balance at September 30, 2013	10,425,000	$0.02	0.18

9.	Subsequent Events

In October 2013 the financing company holding the convertible notes discussed in Note 7 converted $14,000 of a convertible note and received 3,181,818 shares of common stock.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENT NOTICE:

This quarterly report on Form 10-Q and our future filings with the Securities and Exchange Commission contain many forward-looking statements, which involve risks and uncertainties, such as our plans, objective, expectations and intentions. You can identify these statements by our use of words such as “may,” “expect”, “believe”, “anticipate”, “intend”, “could”, “estimate”, “continue”, “plans”, or other similar words or phrases. Some of these statements include discussions regarding our future business strategy and our ability to generate revenue, income, and cash flow. We wish to caution the reader that all forward-looking statements contained in this Form 10-Q are only estimates and predictions. Our actual results could differ materially from those anticipated as a result of risk facing us or actual events differing from the assumptions underlying such forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements contained in this Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements. We undertake no obligation to update any of these factors or to publicly announce any change to our forward-looking statements made herein, whether as a result of new information, future events, changes in expectations or otherwise.

Overview

(a) Our Corporate History.

The Company was incorporated on September 18, 1985, under the laws of the Province of British Columbia under the name of Canadian Comstock Exploration Ltd. with an authorized share capital of 20,000,000 shares without par value.

The Company changed its name on June 7, 1995 to “American Comstock Exploration Ltd.” in connection with a consolidation of its share capital on a one for four basis.

The Company changed its name again on February 4, 1998 to “International Comstock Exploration Ltd.” in connection with a consolidation of its share capital on a one for five basis.

The Company changed its name again on October 2, 2001 to “Secureview Systems Inc.” in connection with a consolidation of its share capital on a one for five basis. In addition, the Company increased its authorized share capital to 100,000,000 shares without par value on October 2, 2001.

The Company changed its name again on May 2, 2005 to “Global Immune Technologies, Inc.” In addition, the Company increased its authorized share capital to an unlimited number of common shares without par value on March 23, 2005.

On February 28, 2006, the Company changed its corporate domicile from British Columbia, Canada to the State of Wyoming.

(b) Business History of the Issuer.

Table of Contents

From its incorporation in 1985 until 1999, the Company has been engaged in the business of exploration of natural resource properties. During 2004 the Company disposed of its final interests in its natural resource properties. In early 1999 the Company initiated a search for other business opportunities culminating in May 1999 with the acquisition of the domain name ProSportsPool.com. In January 2000, the Company entered into an agreement with Internet Sports Network Inc. to develop and maintain a number of internet based games and contests. Internet Sports Network eventually developed "Fantasy Free for All" software and back end support for Nascar, Formula One, Cart series and Baseball and Hockey contests for ProSportsPool.com. The Company launched the ProSportsool.com website on March 1, 2000 with Formula 1 and NASCAR contests "Fantasy Free for All". The launch of the website was accompanied by a marketing campaign that included print, billboard, and internet-banner advertising. In March 21, 2000, the Company engaged Iceberg Media.com Inc. to provide three music channels - 1Groove.com, 2Kool4Radio.com and PrimeTicket.net - for the ProSportsPool.com website. The ProSportsPool.com website added a fantasy baseball contest, and an affiliation with Altavista.com on March 27, 2000. At the beginning of April 2000, the Company launched its internet based hockey contest and announced its inaugural contest winners in its auto-racing contests. The Company also announced it has become an authorized member of the Cnet.com affiliate network and formed similar affiliations with Chipshot.com, Wrenchead.com, Quokka.com and America Online.

To increase awareness of the ProSportspool.com website, the Company participated at the G.I. Joe 200 CART race in Portland, Oregon as well as the Toronto and Vancouver Indy races by appearing at a booth at the races signing up contestants and offering prizes to entrants. On January 15, 2001, due to the closing of Internet Sports Network Inc., which provided the technical architecture and sports data for the ProSportsPool.com’s sports contests, the Company was forced to discontinue its sports-contest site.

During June 2001 and amended October, 2001 the Company entered into a letter of intent with Argent Resources Ltd., On-Track Computer Training Ltd., On-Track Computer International Ltd. and Lute Linux.com Corp. whereby Argent assigned its right to enter into a share exchange agreement with Lute who held the option to enter into a share exchange agreement with On-Track and On-Track International. In exchange for the assignment by Argent to the Company of the share exchange agreement entered into between Lute and Argent, the Company issued 2,000,000 shares and paid $50,000 to Argent.

During October 2001 the Company signed an agreement with Lute Linux.com Corp. including the exchange of Lute share purchase warrants for Company shares at a deemed value of $0.10 US per share, as to Russ Rossi (100,000 shares), RRGS Creative Management Corp. (2,400,000 shares) and Quest Ventures Ltd. (175,000 shares). The Company did not proceed with similar share purchase agreements with On-Track Computer Training Ltd. and On-Track Computer International Ltd. Lute focused its business development on its “Fedcam”, an inexpensive remote monitoring system that allows subscribers to view their target locations via secure website. The “Fedcam” was being tested by the Canadian government's construction branch on its Osoyoos, British Columbia border crossing site into the United States. However, as of March 31, 2003, the Company ceased funding the “Fedcam” and the asset was written down to a nominal amount.

In June 2002 the Company entered into a letter of intent with Estwind Energy, a private power generation company incorporated in Estonia, whereby the Company intended to acquire all of the issued and outstanding shares of Estwind Energy. However, the Company decided against completing the share exchange agreement as the business of Estwind Energy was deemed to not be profitable.

In May 2003 the Company entered into a letter of intent with P-CE Computers, Inc., a private Nevada corporation engaged in the business of developing ergonomic multimedia-computer workstations. The Company decided against completing the share exchange agreement as due diligence indicated that the business of P-CE Computers, Inc. would not be profitable.

In September 2003 the Company entered into a letter of intent with TNR Resources Ltd. (“TNR”), a public British Columbia, Canada, corporation, to purchase a 50% working interest in TNR's Las Carachas property in Argentina. The Company did not pursue the option.

In February 2005 the Company entered an agreement to acquire the rights and interests in a drug, Trioxolane. The Company did not pursue or complete this acquisition.

Table of Contents

Subsequently to March 31, 2005, the Company has agreed to purchase WSG Systems Inc., (“WSG”) its' business and assets from Global Lottery Corporation for the issuance of 100,000,000 shares of common stock. The assets of WSG include proprietary technology, software, its trade names and trademarks as those products pertain to the worldwide lottery industry and/or worldwide pari-mutual betting. The products are designed to be used by all entities in the industry for conducting lotteries and or pari-mutual betting, including corporations and/or governmental agencies representing countries, provinces, states, etc. to implement and/or to improve their lottery and/or pari-mutuel betting systems.

On July 19, 2006, the Company entered into a securities exchange agreement with MediPri Limited, Primemedical International, Ltd. (“MedPri”) and Medical Monitors Limited (“MML”). The transaction was revised on May 17, 2007. The transaction was rescinded on July 11, 2007.

On December 20, 2010, the Company entered into an agreement (“IAT Agreement”) with Mid Atlantic Capital Associates, SL, a Spanish company (the “Assignor”) pursuant to which Assignor assigned to the Company an Agreement dated 11 October 2010, with an addendum dated November 24, 2010 both made with Institute For Applied Technology, (“IAT”) of Germany. IAT purported to own certain solar energy collector technology and related inventions, products, know-how and patents pending. The consideration for the assignment of the IAT. Agreement was 92,000,000 shares of Company Common Stock (the “Shares”), paid to the IAT.

On March 20, 2012 the Agreement for a joint venture was rescinded by the Board of Directors along with the cancellation of the 92,000,000 Shares issued for the purchase and JV.

On December 3, 2012 shareholders owning a majority of the issued shares formally cancelled the share issuance and IAT purchase and Joint Venture. The Shares could not be cancelled so the Company increased the number of outstanding by 92,000,000.

Global Immune Technologies, Inc. is a development stage company and consequently is subject to the risks associated with development stage companies, including the need for additional financing; the uncertainty of our technology and intellectual property resulting in successful commercial products or services as well as the marketing and customer acceptance of such products or services; competition from larger organizations; dependence on key personnel; and dependence on corporate partners and collaborators. Our Company Web site URL is: http://www.globalimmunetechnologies.com

Global Immune Technologies, Inc. is in the early initial planning stages as a holding company of an American-based food distribution company serving direct delivery to the customer at their homes. The food items will be sold by telemarketing to the customer and delivered by our own trucks to homes on a scheduled basis. Customers can choose their new re-order items via the Internet. Meat, poultry and fish items will be packed in individual portions at our food processing plants and frozen for freshness. We intend to offer meat, chicken and seafood as well as other food products. These other items are name brand canned and jarred foods like Mott’s Apple Sauce, Dole Pineapple, Jiff peanut butter, tinned tuna fish & salmon and the like.

The Company is seeking persons interested in supplying us with capital to begin operations. We still have limited capital and will focus our initial operations to one or two such business locations to be able to take advantage of this business opportunities. The Company intends to seek other opportunities demonstrating the potential of long-term growth as opposed to short-term earnings. However, at the present time, the Company has not reached any agreement or definitive understanding with any person concerning an acquisition. Rather, we intend to build from start-up instead of incurring expensive acquisition costs.

SBC Foods Capital of America Inc., our wholly-owned subsidiary (“SRC Foods”) intends to enter into a partnership with Les Aliments S.R.C. Inc. Canada (“Les Aliments”) to launch two operating companies in the USA under the trading names of SRC Food Concept of America and SRC Food Franchising of America with the latter to launch in the middle of 2014.

Les Aliments has been in the food & hospitality industry over the past 30 years and has built a very strong network globally, and understands the need for providing clients worldwide with quality food products. SRC Foods originally created in April 2013 and based at our food division’s head office in Vermont.

Table of Contents

Comparison of three months ended September 30 2013 with the three months ended June 30, 2012

During the three month periods ended September 30, 2012 and September 30, 2013, we did not experience revenues from operations.

Operating expenses for the period July 1, 2013 to September 30, 2013 was $(67,377 ) compared to the same three month period from July 1, 2012 to September 30, 2012 was $(142,621). The decrease in expense is primarily due to the reduction in monies spent (i) on rehabilitating the Company, (ii) settling old debts, (iii) keeping current the accounting, (iv) on developing new business plans for the future operations of the Company and (v) funding new subsidiaries.

Plan of Operation and Funding

We will need to raise capital in order to commence our proposed business operations. No assurance can be given that we will be able to raise sufficient capital to implement any proposed business operations. We have not identified any specific future financing sources.

In the future, our efforts to finance the Company may result in the issuance of equity and debt instruments. This and other future financing activity, if any, may result in the dilution of shareholder equity. We expect to incur financial losses for the foreseeable future.

Acquisition or Disposition of Plant and Equipment

We do not anticipate the acquisition or disposition of any significant property, plant or equipment during the next 12 months

From our inception through the period ended June 30, 2013, we have relied on the services of outside consultants for services and currently have four part-time employees. In order for us to attract and retain quality personnel, we anticipate we will have to offer competitive salaries to future employees.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Not Applicable to Smaller Reporting Companies.

Item 4. Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures.

As of the end of the reporting period, September 30, 2013, we carried out an evaluation, under the supervision and with the participation of our management, including the Company's Chairman and Chief Executive Officer/Principal Accounting Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(e) of the Securities

Table of Contents

Exchange Act of 1934 (the "Exchange Act"), which disclosure controls and procedures are designed to insure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized and reported within required time periods specified by the SEC's rules and forms. Based upon that evaluation, the Chairman/CEO and the Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to the Company required to be included in the Company's period SEC filings. We filed the report to the US Securities and Exchange Commission on Form 10-Q for the period December 31, 2012 on time. We filed the annual report to the United States Securities and Exchange Commission on Form 10-K for the period March 31, 2013 on time.

We have for this report to the US Securities and Exchange Commission on Form 10-Q for the period September 30, 2013 and our future needs engaged the accounting firm of Montgomery and Merrill PC, certified public accountants of Burlington, Vermont. They will work with management as outside consultants and interface with our auditor, Donahue and Associates.

(b) Changes in Internal Control.

Subsequent to the date of such evaluation as described in subparagraph (a) above, there were no changes in our internal controls or other factors that could significantly affect these controls, including any corrective action with regard to significant deficiencies and material weaknesses.

Our management, including our Principal Executive Officer and Principal Financial Officer, does not expect that our disclosure controls or internal controls over financial reporting will prevent all errors or all instances of fraud. However, we believe that our disclosure controls and procedures are designed to provide reasonable assurance of achieving this objective. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and any design may not succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitation of a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Table of Contents

PART II-OTHER INFORMATION

Item 1. Legal Proceedings.

We are currently not involved in any litigation that we believe could have a materially adverse effect on our financial condition or results of operations.

The Company's common shares are registered under Section 12(g) of the Securities Exchange Act of 1934, as amended. Prior to February 28, 2006, it filed as a foreign registrant and after that date filed as a U.S. reporting registrant. The Company has been subject to the reporting obligations of the provinces of British Columbia and Alberta, Canada.

Prior to February 28, 2006, Global Immune Technologies, Inc. was a corporation organized under the laws of British Columbia, Canada. On February 28, 2006, the Company changed its corporate domicile to the State of Wyoming. The British Columbia corporation was formally dissolved June 2, 2006.

The Company's common stock has been quoted Over-the-Counter on the FINRA BB, the Pink Sheets and recently the OTC QB tier. The Company’s shares are not quoted on any Canadian market.

The Company has 17 British Columbia and 1 Alberta shareholder on its shareholder's list.

Foreign Regulatory: Canada

On August 11, 2005, the Company's predecessor, Global Immune Technologies, Inc., then a company organized under the laws of British Columbia, Canada, received a Cease Trade Order (CTO) from the British Columbia Securities Commission, (the "BCSC"), which was limited to the Province of British Columbia, Canada, for not filing comparative financial statements for its financial year ended March 31, 2005 as required under Part 4 of National Instrument 51-102 Continuous Disclosure Obligations, and had not filed Form 51-102F1 Management's Discussion and Analysis for the periods ended December 31, 2004 and March 31, 2005, as required by Part 5 of NI 51-102.

On March 5, 2007, the Company received a Cease Trade Order (CTO) from the Alberta Securities Commission (the "ASC") which was limited to the Province of Alberta, Canada, for not filing annual audited financial statements for the year ended March 31, 2006, interim unaudited financial statements for the interim periods ended December 31, 2005, June 30, 2006, December 31, 2006 and December 31, 2006.

The Company requested exemptive relief and was granted a Revocation Order on March 4, 2011 removing the Cease Trade Order in the provinces of British Columbia and Alberta.

Item 1A. Risk Factors.

Not Applicable.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds.

On July 23, 2013 we issued 9,826,019 shares of Common Stock for previously subscribed to shares of $271,590 in private placements. All funds received from the sale our securities were used for working capital purposes.

All securities bear a legend restricting their disposition.

Net cash provided by financing activities for the period April 1, 2013 to September 30, 2013 was approximately $486,557; and from April 1, 2012 to September 30, 2012 was $-0-. This consisted of net proceeds received from the sale of shares to be issued for cash. The funds were used for general operating expenses. The securities subscribed to bear a legend restricting their disposition.

Table of Contents

Item 3. Defaults upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not Applicable

Item 5. Other Information.

Not Applicable

Subsequent Events

The net proceeds from the Notes referred to in Note 7 to the Financial Statements of approximately $60,000.00 were apparently utilized for personal reasons by Jeffery R. Bruhjell, a current director and a former officer of the Company. This amount plus an approximate additional $20,000, as advance for moving expenses which did not happen, were re-classified on the Balance Sheet as loans due from employees.

Item 6. Exhibits

Exhibits Index

31.1 Section 302 Certification of Chief Executive Officer

31.2 Section 302 Certification of Chief Financial Officer

32.1 Section 906 Certification of Chief Executive Officer

32.2 Section 906 Certification of Chief Financial Officer

101.INS XBRL Instance Document

101.SCH XBRL Taxonomy Extension Schema

101.CAL XBRL Taxonomy Extension Calculation Linkbase

101.DEF XBRL Taxonomy Extension Definition Linkbase

101.LAB XBRL Taxonomy Extension Label Linkbase

101.PRE XBRL Taxonomy Extension Presentation Linkbase

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

November 19, 2013

	Global Immune Technologies, Inc.

	/s/ Serge Talon:
	Serge Talon
	Title: President &
	Chief Executive Officer (CEO)

	/s/ Serge Talon
	Serge Talon
	Chief Financial Officer (CFO)
	Principal Accounting Officer (PAO)

Global Immune Technologies Inc. 10-Q